
Biologics are defined as pharmaceutical products obtained from living cells or microorganisms.
The global Biologics Drug Development market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Biologics Drug Development, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biologics Drug Development.
Report Scope
The Biologics Drug Development market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Biologics Drug Development market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biologics Drug Development companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Abbvie
Allergan
Boehringer Ingelheim
Charles River Laboratories
Catalent
Lonza Group
Amgen
Sanofi
Segment by Type
Clinical Manufacturing
Formulation Development
Bioassay Development
Analytical Services
Segment by Application
In-House
Outsource
Pharma Excess
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Biologics Drug Development companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Biologics Drug Development Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Clinical Manufacturing
1.2.3 Formulation Development
1.2.4 Bioassay Development
1.2.5 Analytical Services
1.3 Market by Application
1.3.1 Global Biologics Drug Development Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 In-House
1.3.3 Outsource
1.3.4 Pharma Excess
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Biologics Drug Development Market Perspective (2019-2030)
2.2 Biologics Drug Development Growth Trends by Region
2.2.1 Global Biologics Drug Development Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Biologics Drug Development Historic Market Size by Region (2019-2024)
2.2.3 Biologics Drug Development Forecasted Market Size by Region (2025-2030)
2.3 Biologics Drug Development Market Dynamics
2.3.1 Biologics Drug Development Industry Trends
2.3.2 Biologics Drug Development Market Drivers
2.3.3 Biologics Drug Development Market Challenges
2.3.4 Biologics Drug Development Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Biologics Drug Development Players by Revenue
3.1.1 Global Top Biologics Drug Development Players by Revenue (2019-2024)
3.1.2 Global Biologics Drug Development Revenue Market Share by Players (2019-2024)
3.2 Global Biologics Drug Development Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Biologics Drug Development Revenue
3.4 Global Biologics Drug Development Market Concentration Ratio
3.4.1 Global Biologics Drug Development Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Biologics Drug Development Revenue in 2023
3.5 Biologics Drug Development Key Players Head office and Area Served
3.6 Key Players Biologics Drug Development Product Solution and Service
3.7 Date of Enter into Biologics Drug Development Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Biologics Drug Development Breakdown Data by Type
4.1 Global Biologics Drug Development Historic Market Size by Type (2019-2024)
4.2 Global Biologics Drug Development Forecasted Market Size by Type (2025-2030)
5 Biologics Drug Development Breakdown Data by Application
5.1 Global Biologics Drug Development Historic Market Size by Application (2019-2024)
5.2 Global Biologics Drug Development Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Biologics Drug Development Market Size (2019-2030)
6.2 North America Biologics Drug Development Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Biologics Drug Development Market Size by Country (2019-2024)
6.4 North America Biologics Drug Development Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Biologics Drug Development Market Size (2019-2030)
7.2 Europe Biologics Drug Development Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Biologics Drug Development Market Size by Country (2019-2024)
7.4 Europe Biologics Drug Development Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Biologics Drug Development Market Size (2019-2030)
8.2 Asia-Pacific Biologics Drug Development Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Biologics Drug Development Market Size by Region (2019-2024)
8.4 Asia-Pacific Biologics Drug Development Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Biologics Drug Development Market Size (2019-2030)
9.2 Latin America Biologics Drug Development Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Biologics Drug Development Market Size by Country (2019-2024)
9.4 Latin America Biologics Drug Development Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Biologics Drug Development Market Size (2019-2030)
10.2 Middle East & Africa Biologics Drug Development Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Biologics Drug Development Market Size by Country (2019-2024)
10.4 Middle East & Africa Biologics Drug Development Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Abbvie
11.1.1 Abbvie Company Detail
11.1.2 Abbvie Business Overview
11.1.3 Abbvie Biologics Drug Development Introduction
11.1.4 Abbvie Revenue in Biologics Drug Development Business (2019-2024)
11.1.5 Abbvie Recent Development
11.2 Allergan
11.2.1 Allergan Company Detail
11.2.2 Allergan Business Overview
11.2.3 Allergan Biologics Drug Development Introduction
11.2.4 Allergan Revenue in Biologics Drug Development Business (2019-2024)
11.2.5 Allergan Recent Development
11.3 Boehringer Ingelheim
11.3.1 Boehringer Ingelheim Company Detail
11.3.2 Boehringer Ingelheim Business Overview
11.3.3 Boehringer Ingelheim Biologics Drug Development Introduction
11.3.4 Boehringer Ingelheim Revenue in Biologics Drug Development Business (2019-2024)
11.3.5 Boehringer Ingelheim Recent Development
11.4 Charles River Laboratories
11.4.1 Charles River Laboratories Company Detail
11.4.2 Charles River Laboratories Business Overview
11.4.3 Charles River Laboratories Biologics Drug Development Introduction
11.4.4 Charles River Laboratories Revenue in Biologics Drug Development Business (2019-2024)
11.4.5 Charles River Laboratories Recent Development
11.5 Catalent
11.5.1 Catalent Company Detail
11.5.2 Catalent Business Overview
11.5.3 Catalent Biologics Drug Development Introduction
11.5.4 Catalent Revenue in Biologics Drug Development Business (2019-2024)
11.5.5 Catalent Recent Development
11.6 Lonza Group
11.6.1 Lonza Group Company Detail
11.6.2 Lonza Group Business Overview
11.6.3 Lonza Group Biologics Drug Development Introduction
11.6.4 Lonza Group Revenue in Biologics Drug Development Business (2019-2024)
11.6.5 Lonza Group Recent Development
11.7 Amgen
11.7.1 Amgen Company Detail
11.7.2 Amgen Business Overview
11.7.3 Amgen Biologics Drug Development Introduction
11.7.4 Amgen Revenue in Biologics Drug Development Business (2019-2024)
11.7.5 Amgen Recent Development
11.8 Sanofi
11.8.1 Sanofi Company Detail
11.8.2 Sanofi Business Overview
11.8.3 Sanofi Biologics Drug Development Introduction
11.8.4 Sanofi Revenue in Biologics Drug Development Business (2019-2024)
11.8.5 Sanofi Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Abbvie
Allergan
Boehringer Ingelheim
Charles River Laboratories
Catalent
Lonza Group
Amgen
Sanofi
Ìý
Ìý
*If Applicable.
